Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + TKI in EGFR-mutated NSCLC
NCT03071705Phase 2Unknown
- Start
- Mar 2016
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liquid metformin (Aspargo Labs) in non-small cell lung cancer (NSCLC). Primary endpoints: Progression-Free Survival and Overall Survival at 1 year. Status: unknown.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03071705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03071705.